Skip to main content

Drug Interactions between Dexamethasone Intensol and ruxolitinib topical

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

dexAMETHasone ruxolitinib topical

Applies to: Dexamethasone Intensol (dexamethasone) and ruxolitinib topical

Coadministration with inducers of CYP450 3A4 may decrease plasma concentrations (Cmax) and systemic exposure (AUC) of topical ruxolitinib, which is primarily metabolized by the isoenzyme. Following administration of rifampin (600 mg once daily for 10 days), a potent CYP450 3A4 inducer, healthy subjects then received a single dose of ruxolitinib (50 mg orally). The Cmax and AUC of ruxolitinib decreased 32% and 61% respectively, compared to healthy subjects receiving the oral ruxolitinib dose alone. However, the clinical significance of this effect on a topical formulation is unknown. Consultation with individual package labeling, as well as relevant institutional protocols, may be advisable for further guidance. Clinical data for less potent inducers are not available.

References (2)
  1. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation
  2. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation, 2

Drug and food interactions

Major

ruxolitinib topical food

Applies to: ruxolitinib topical

MONITOR CLOSELY: Smoking during treatment with topical ruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies, including lymphomas. During clinical trials, patients who were current or past smokers and received oral Janus Kinase (JAK) inhibitors to treat inflammatory conditions had an additional increased risk of overall malignancies. Additionally, oral JAK inhibitors reportedly increase patients' risk of MACE, including cardiovascular death, myocardial infarction, and stroke, particularly in patients who are current or past smokers or patients with other cardiovascular risk factors.

MANAGEMENT: The potential risks and benefits of topical ruxolitinib should be carefully weighed prior to initiating therapy, particularly in patients with cardiovascular risk factors, as well as those with a history of malignancy, those who develop a malignancy while on treatment, and/or patients who are current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing topical ruxolitinib in patients who have experienced a myocardial infarction or stroke.

References (2)
  1. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation
  2. (2024) "Product Information. Opzelura (ruxolitinib topical)." Incyte Corporation, 2

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer